Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979947 | 1.00 | OPRK1 (0.49) | OPRK1OPRL1KDM1AOPRM1HDAC1 | |
| SCHEMBL3237114 | 0.88 | KDM1A (0.49) | OPRK1OPRL1KDM1AHDAC1HDAC8 | |
| SCHEMBL3237107 | 0.88 | KDM1A (0.49) | OPRK1OPRL1KDM1AHDAC1HDAC8 | |
| SCHEMBL17586462 | 0.86 | KDM1A (0.43) | OPRK1OPRL1KDM1AOPRM1HDAC1 | |
| SCHEMBL10253956 | 0.86 | OPRL1 (0.48) | OPRK1OPRL1KDM1AOPRM1HDAC1 | |
| SCHEMBL13480119 | 0.85 | OPRL1 (0.54) | OPRK1OPRL1KDM1AOPRM1HDAC1 | |
| SCHEMBL20955524 | 0.85 | IP6K1 (0.48) | OPRK1OPRL1OPRM1OPRD1PDK2 | |
| SCHEMBL30898647 | 0.85 | KDM1A (0.47) | OPRK1KDM1AHDAC1HDAC8HDAC6 | |
| SCHEMBL4792337 | 0.85 | KDM1A (0.47) | OPRK1OPRL1KDM1AHDAC1HDAC8 | |
| SCHEMBL13480003 | 0.85 | OPRM1 (0.52) | OPRK1OPRL1OPRM1OPRD1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | OPRK1 6/4885OPRL1 1/4885KDM1A 1128/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | OPRK1 1161/4885OPRL1 923/4885KDM1A 1637/4885 |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | OPRK1 3/4885OPRL1 1/4885KDM1A 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.